Allergan and Heptares Announce Global R&D and Commercialization Partnership

 

DUBLIN and LONDON, April 6, 2016Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited and Heptares have entered into a definitive agreement under which Allergan will license exclusive global rights to a broad portfolio of novel subtype-selective muscarinic receptor agonists in development for the treatment of major neurological disorders, including Alzheimer’s disease.

Subscribe to get the latest news